Verona pharma to present seven analyses of the phase 3 enhance studies in copd at ats 2025

Analyses support ohtuvayre® (ensifentrine) as a first-in-class selective dualinhibitor of pde3 and pde4 for a broad copd population
VRNA Ratings Summary
VRNA Quant Ranking